Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Mylan Inc. Stories

2013-12-17 16:23:22

Agreement includes a no-later-than July 9, 2015 launch PITTSBURGH, Dec. 17, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will resolve patent litigation related to Bexarotene Capsules, 75 mg. Bexarotene is the generic...

2013-12-05 08:29:16

PITTSBURGH, Dec. 5, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Cabergoline Tablets USP, 0.5 mg. Cabergoline Tablets USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Cabergoline Tablets...

2013-12-04 16:25:54

Purchase Price Restructured to Hold Back $250 Million Contingent Upon Satisfaction of Certain Regulatory Conditions PITTSBURGH, Dec. 4, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has completed the acquisition of the Agila injectables businesses from Strides Arcolab Limited (BSE: 532531, NSE: STAR) for up to $1.75 billion, which includes $250 million in contingent consideration. Since the initial announcement of this acquisition, the final transaction...

2013-12-04 08:29:45

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, December 4, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Merck & Co. Inc. (NYSE: MRK), Varian Medical Systems Inc. (NYSE: VAR), Mylan Inc. (NASDAQ: MYL), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Abiomed Inc. (NASDAQ: ABMD). Today's readers may access these reports free of charge - including full price targets, industry analysis and...

2013-12-01 08:20:28

PITTSBURGH, Dec. 1, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading pharmaceutical companies, and the Elton John AIDS Foundation (EJAF) today announced that they will give a combined $1 million to the Business Leadership Council for a Generation Born HIV Free (BLC) for the elimination of mother-to-child transmission (eMTCT) of HIV in Nigeria. Nigeria is home to 3.4 million people living with HIV, with approximately 60,000 children newly infected with the...

2013-11-25 12:27:04

PITTSBURGH, Nov. 25, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India. This is the first regulatory approval for a Mylan-Biocon developed biosimilar product. The product is a biosimilar to Roche's Herceptin®, indicated for the treatment of HER2 overexpressing breast cancer. Mylan intends to market its trastuzumab product under the trade name...

2013-11-25 08:27:17

PITTSBURGH, Nov. 25, 2013 /PRNewswire/ -- Teva Pharmaceutical Industries (NYSE: TEVA) and Mylan Inc. (NASDAQ: MYL) today announce that certain of their affiliates have agreed to settle and dismiss pending patent litigation involving Copaxone® (glatiramer acetate) in the United Kingdom, the Netherlands and France relating to non-infringement and the validity of European Patent 0,762,888, which expires in May 2015. The terms of the settlement are confidential. Mylan is a global...

2013-11-19 16:26:12

PITTSBURGH, Nov. 19, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the pricing of a registered offering of aggregate principal amount of $2.0 billion in bond issuance comprised of: -- $500 million aggregate principal amount of 1.35% Senior Notes due 2016; -- $500 million aggregate principal amount of 2.55% Senior Notes due 2019; -- $500 million aggregate principal amount of 4.20% Senior Notes due 2023; and -- $500 million aggregate principal...

2013-11-18 08:28:12

- Company awarded 180 days marketing exclusivity - PITTSBURGH, Nov. 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Dexmethylphenidate Hydrochloride Extended-release (ER) Capsules, 30 mg, which is the first generic version of Novartis' Focalin XR(®). Mylan was the first company to have filed a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV patent certification for...

2013-11-14 08:33:20

PITTSBURGH, Nov. 14, 2013 /PRNewswire/ -- Mylan Inc. (NASDAQ: MYL) commends federal legislation signed by President Barack Obama yesterday aimed at protecting people living with potentially life-threatening allergies. The School Access to Emergency Epinephrine Act (H.R. 2094), encourages states to adopt laws allowing schools to maintain a supply of "stock," or undesignated, epinephrine - the only first-line treatment for life-threatening allergic reactions (anaphylaxis). "Recent...